Author:
Palmer J M,Amoaku W M,Kamali F
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Genentech. Avastin. Summary of product characteristics. January 2010. Available at
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf
. (accessed July 2012).
2. Novartis. Lucentis summary of product characteristics. January 2012. Available at
http://www.medicines.org.uk/emc/history/19409/SPC/Lucentis+10+mg+ml+solution+for+injection
. (accessed July 2012).
3. Rich RM, Rosenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn HW Jr et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495–511.
4. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ . Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897–1908.
5. Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration. Ophthalmology 2012; 119: 1399–1411.
Cited by
38 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献